FEED Company Profile and Key Details

FEED has shown weak momentum, losing -46.05% over the past week and -79.06% over the past quarter, though year-to-date performance is down -46.75%. Short-term trend indicators are mixed aligned (SMA20 -19.42%, SMA50 -8.7%, SMA200 -65.65%). The stock’s 14-day RSI is 44.95 (neutral), while the ATR of 0.55 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -98.61% below its high and over 128.28% above its low. Average 10-day trading volume of 266.27 thousand shares is below the 3-month average of 10.50 million, indicating normal recent market interest.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

ENvue Medical, Inc. generated EPS of -$96.17 over the past year. Five-year average earnings growth is 40.47%.

ENvue Medical, Inc. (NASDAQ:FEED) shares are down -46.75% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows ENvue Medical, Inc. trading at a premium to the broader market with a P/E of -0.55. Our AI forecast model points to short-term weakness (-46.15% over two weeks), a medium-term fall (-57.34% over three months), and a longer-term loss (-99.3% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that ENvue Medical, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -46.15%, with price expected at $0.77 by April 06, 2026, within a range of $0.46 to $1.08 3-Month Outlook: Projected fall of -57.34%, reaching $0.61 by June 19, 2026, with a range of $0.53 to $0.68. 1-Year Outlook: Projected loss of -99.3%, with price at $0.01 by March 23, 2027, within a range of $0.00 to $0.10.

ENvue Medical, Inc. (NASDAQ:FEED) closed at $2.26 USD, gaining $0.83 (58.04%) from the previous close of $1.43. The stock is currently mid-range between its 52-week high and low $1.00 and $5.98. With a market capitalization of about $2.46 million, ENvue Medical, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~2.28). Headquartered in Tyler, None, ENvue Medical, Inc. operates in the Healthcare sector and the Medical - Specialties industry. Led by CEO Doron Robert Besser, the company employs approximately 31 people and listed since December 12, 2025. NanoVibronix, Inc. engages in the development of noninvasive biological response-activating devices.

ENvue Medical, Inc. trades at a P/E ratio of -0.55, slightly below the S&P 500 average, with a price-to-sales ratio of 0.9 and a price-to-book ratio of 0.04 suggesting the stock is closer to book value. The P/FCF stands at -0.32, also below market averages.